SpaceX Surpasses Amazon in Market Value as Post-IPO Rally Accelerates 
John Jumper Leaves Google DeepMind for Anthropic Amid Intensifying AI Talent Race 
Microsoft Taps AWS to Support GitHub Amid AI Coding Boom 
Chinese Social Media Giant Xiaohongshu Eyes Hong Kong IPO at Over $70 Billion Valuation 
SpaceX Stock Slides After IPO Rally as Valuation Concerns Grow 
Apple Signals Product Price Hikes Amid Rising Memory Chip Costs 
Saudi Aramco Explores Sulphur Business Stake Sale to Raise Billions 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
Jio IPO Filing Nears as Reliance Targets $4 Billion Market Debut 
G7 Explores AI Access Deal With U.S. Amid Anthropic Restrictions 
Qantas Nears Launch of World’s Longest Non-Stop Flights to London and New York 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
HSBC Australia Faces A$35M Penalty Over Scam Protection Failures 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
GM and Lockheed Martin Partner to Strengthen U.S. Defense Manufacturing Capacity 
Carro Expands Into Australia With Acquisition of Used-Car Platform CarPlace 
GAITHERSBURG, Md., Dec. 08, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that management will participate in the Guggenheim Securities 3rd Annual Boston Healthcare Conference.
Conference details are as follows:
Date: Tuesday, December 15, 2015
Forum: One-on-one meetings
Location: The Langham Boston, Boston, MA
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the Company’s website, novavax.com.
Contact: Novavax, Inc. Barclay A. Phillips SVP, Chief Financial Officer and Treasurer Andrea N. Flynn, Ph.D. Senior Manager, Investor Relations [email protected] 240-268-2000 Russo Partners, LLC David Schull Todd Davenport, Ph.D. [email protected] [email protected] 212-845-4271
